Terns Pharmaceuticals Announces Completion and Positive Results from Phase 1 Clinical Trial of TERN-201, a SSAO Inhibitor in Development for NASH
Excerpt from the Press Release:
“FOSTER CITY, Calif. & SHANGHAI–(BUSINESS WIRE)–Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative therapies to treat liver disease and cancer, today announced positive results from its completed Phase 1 single ascending dose and multiple ascending dose study of TERN-201, a semicarbazide-sensitive amine oxidase (SSAO) inhibitor, being developed for the treatment of non-alcoholic steatohepatitis (NASH). The data from the first-in-human clinical study of TERN-201 demonstrate that single and multiple oral administrations of TERN-201 were well tolerated with no significant safety findings observed. Each dose level studied showed potent target engagement and achieved near complete inhibition of plasma SSAO activity that was maintained up to one week after single dose or repeat dose administrations of TERN-201.”
Click the button below to read the Press Release:
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?